Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate

Zhang,Yan; Shao,Jin; Wang,Zhi; Yang,Tieyi; Liu,Shuyi; Liu,Yue; Fan,Xinbing; Ye,Weiguang

doi:10.3892/ijmm.2016.2622

Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate

Authors:
- Yan Zhang
- Jin Shao
- Zhi Wang
- Tieyi Yang
- Shuyi Liu
- Yue Liu
- Xinbing Fan
- Weiguang Ye
View Affiliations

Affiliations: Department of Orthopaedics, Gongli Hospital of Pudong New Area, Shanghai 200135, P.R. China
Published online on: June 3, 2016 https://doi.org/10.3892/ijmm.2016.2622
Pages: 491-498

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed in order to examine bone loss and calcium homeostasis in mice with glucocorticoid (GC)-induced osteoporosis (GIOP) following treatment with the aqueous extract of pomegranate seed (AE-PS). In addition, a comparative study with alendronate was performed. Biomarkers in the serum and the urine were measured. The tibias, kidney and duodenum were removed in order to measure the levels of bone calcium, protein expression as well as to perform histomorphological analysis of the bone. GC treatment facilitated the induction of hypercalciuria in the mice, and the AE-PS‑treated mice exhibited a greater increase in serum calcium and a decrease in urine calcium. The AE-PS reversed the deleterious effects on the trabecular bone induced by DXM and stimulated bone remodeling, including an increase in bone calcium and alkaline phosphatase‑b (ALP-b) and a decrease in a the critical bone resorption markers C-terminal telopeptide of type I collagen (CTX) and tartrate‑resistant acid phosphatase-5b (TRAP-5b). Hematoxylin and eosin (H&E) staining revealed the increased disconnections and separation between the growth plate and the trabecular bone network as well as the reduction in the trabecular bone mass of the primary and secondary spongiosa throughout the proximal metaphysis of the tibia in the DXM group. Moreover, the decreased protein expression of transient receptor potential vanilloid (TRPV)5, TRPV6 and calbindin‑D9k (CaBP‑9k) was reversed by the AE-PS or alendronate supplementation in the kidneys and the duodenum as well as plasma membrane Ca2+‑ATPase1 (PMCA1) expression in the kidneys of mice with GIOP. There was no marked difference in pharmacological effectiveness between alendronate and the AE-PS. Taken together, these findings suggest that the AE-PS may be an alternative therapy suitable for use in the management of secondary osteoporosis.

View Figures

View References

1	Zhou DA, Zheng HX, Wang CW, Shi D and Li JJ: Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. BMC Musculoskelet Disord. 15:2392014. View Article : Google Scholar : PubMed/NCBI
2	Scudeletti M, Musselli C, Lanza L, Peirano L, Puppo F and Indiveri F: The immunological activity of corticosteroids. Recenti Prog Med. 87:508–515. 1996.In Italian. PubMed/NCBI
3	Lin H, Wei B, Li G, Zheng J, Sun J, Chu J, Zeng R and Niu Y: Sulforaphane reverses glucocorticoid-induced apoptosis in osteoblastic cells through regulation of the Nrf2 pathway. Drug Des Devel Ther. 8:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
4	Steinbuch M, Youket TE and Cohen S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 15:323–328. 2004. View Article : Google Scholar : PubMed/NCBI
5	Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM and Cooper C: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48:3224–3229. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bitto A, Polito F, Burnett B, Levy R, Di Stefano V, Armbruster MA, Marini H, Minutoli L, Altavilla D and Squadrito F: Protective effect of genistein aglycone on the development of osteonecrosis of the femoral head and secondary osteoporosis induced by methylprednisolone in rats. J Endocrinol. 201:321–328. 2009. View Article : Google Scholar : PubMed/NCBI
7	Reid IR: Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol. 137:209–217. 1997. View Article : Google Scholar : PubMed/NCBI
8	Capozzi A, Casa SD, Altieri B and Pontecorvi A: Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. Clin Cases Miner Bone Metab. 10:199–202. 2013.
9	De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C and Van Staa TP: Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 56:208–214. 2007. View Article : Google Scholar
10	McIlwain HH: Glucocorticoid-induced osteoporosis: Pathogenesis, diagnosis, and management. Prev Med. 36:243–249. 2003. View Article : Google Scholar : PubMed/NCBI
11	Yoon HY, Won YY and Chung YS: Poncirin prevents bone loss in glucocorticoid-induced osteoporosis in vivo and in vitro. J Bone Miner Metab. 30:509–516. 2012. View Article : Google Scholar : PubMed/NCBI
12	Jahn K, Lara-Castillo N, Brotto L, Mo CL, Johnson ML, Brotto M and Bonewald LF: Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cell Mater. 24:197–210. 2012.
13	Ma X, Zhang X, Jia Y, Zu S, Han S, Xiao D, Sun H and Wang Y: Dexamethasone induces osteogenesis via regulation of hedgehog signalling molecules in rat mesenchymal stem cells. Int Orthop. 37:1399–1404. 2013. View Article : Google Scholar : PubMed/NCBI
14	Duzen O, Erkoc R, Begenik H, Soyoral YU and Aldemir MN: The course of hypercalciuria and related markers of bone metabolism parameters associated with corticosteroid treatment. Ren Fail. 34:338–342. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kinoshita Y, Masuoka K, Miyakoshi S, Taniguchi S and Takeuchi Y: Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. 42:226–228. 2008. View Article : Google Scholar
16	Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H and Yoshimura H: Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol. 92:93–101. 2004. View Article : Google Scholar : PubMed/NCBI
17	Saravani M, Kazemi Mehrjerdi H, Mirshahi A and Afkhami Goli A: Protective effects of pomegranate seed oil on ovariectomized rats as a model of postmenopausal osteoporosis: a multi-detector computed tomography evaluation. Vet Res Forum. 5:263–267. 2014.
18	Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M and Amir R: Antioxidant activity, polyphenol content, and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. J Agric Food Chem. 55:9559–9570. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hasnaoui N, Wathelet B and Jiménez-Araujo A: Valorization of pomegranate peel from 12 cultivars: dietary fibre composition, antioxidant capacity and functional properties. Food Chem. 160:196–203. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, et al: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. 71:203–217. 2002. View Article : Google Scholar : PubMed/NCBI
21	Spilmont M, Léotoing L, Davicco MJ, Lebecque P, Mercier S, Miot-Noirault E, Pilet P, Rios L, Wittrant Y and Coxam V: Pomegranate seed oil prevents bone loss in a mice model of osteoporosis, through osteoblastic stimulation, osteoclastic inhibition and decreased inflammatory status. J Nutr Biochem. 24:1840–1848. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lou Q-Q, Zhang Y-F, Zhou Z, Shi YL, Ge YN, Ren DK, Xu HM, Zhao YX, Wei WJ and Qin ZF: Effects of perfluorooctanesulfonate and perfluorobutanesulfonate on the growth and sexual development of Xenopus laevis. Ecotoxicology. 22:1133–1144. 2013. View Article : Google Scholar : PubMed/NCBI
23	Shuid AN and Mohamed IN: Pomegranate use to attenuate bone loss in major musculoskeletal diseases: an evidence-based review. Curr Drug Targets. 14:1565–1578. 2013. View Article : Google Scholar : PubMed/NCBI
24	Spilmont M, Léotoing L, Davicco MJ, Lebecque P, Mercier S, Miot-Noirault E, Pilet P, Rios L, Wittrant Y and Coxam V: Pomegranate and its derivatives can improve bone health through decreased inflammation and oxidative stress in an animal model of postmenopausal osteoporosis. Eur J Nutr. 53:1155–1164. 2014. View Article : Google Scholar
25	Mok CC, Ho LY and Ma KM: Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 75:222–228. 2015. View Article : Google Scholar : PubMed/NCBI
26	Bitto A, Burnett BP, Polito F, Levy RM, Marini H, Di Stefano V, Irrera N, Armbruster MA, Minutoli L, Altavilla D and Squadrito F: Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. Br J Pharmacol. 156:1287–1295. 2009. View Article : Google Scholar : PubMed/NCBI
27	Lin H, Gao X, Chen G, Sun J, Chu J, Jing K, Li P, Zeng R and Wei B: Indole-3-carbinol as inhibitors of glucocorticoid-induced apoptosis in osteoblastic cells through blocking ROS-mediated Nrf2 pathway. Biochem Biophys Res Commun. 460:422–427. 2015. View Article : Google Scholar : PubMed/NCBI
28	Jia D, O'Brien CA, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 147:5592–5599. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yongtao Z, Kunzheng W, Jingjing Z, Hu S, Jianqiang K, Ruiyu L and Chunsheng W: Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis. Endocrine. 47:598–608. 2014. View Article : Google Scholar : PubMed/NCBI
30	Tamura Y, Kawao N, Yano M, Okada K, Okumoto K, Chiba Y, Matsuo O and Kaji H: Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice. Diabetes. 64:2194–2206. 2014. View Article : Google Scholar
31	Zhang Y, Diao TY, Wang L, Che CT and Wong MS: Protective effects of water fraction of Fructus Ligustri Lucidi extract against hypercalciuria and trabecular bone deterioration in experimentally type 1 diabetic mice. J Ethnopharmacol. 158(Pt A): 239–245. 2014. View Article : Google Scholar : PubMed/NCBI
32	Sonntag J and Gaude M: Effect of dexamethasone and spironolactone therapy in calcium and phosphate homeostasis in premature infants with a birth weight under 1,500 g. Klin Padiatr. 210:354–357. 1998.In German. View Article : Google Scholar : PubMed/NCBI
33	Lin YJ, Yeh TF, Lin HC, Wu JM, Lin CH and Yu CY: Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatr. 87:1061–1065. 1998. View Article : Google Scholar : PubMed/NCBI
34	Hoenderop JG, Nilius B and Bindels RJ: Calcium absorption across epithelia. Physiol Rev. 85:373–422. 2005. View Article : Google Scholar
35	Alexander RT, Rievaj J and Dimke H: Paracellular calcium transport across renal and intestinal epithelia. Biochem Cell Biol. 92:467–480. 2014. View Article : Google Scholar : PubMed/NCBI
36	Nijenhuis T, Hoenderop JG and Bindels RJ: TRPV5 and TRPV6 in Ca²⁺ (re)absorption: regulating Ca²⁺ entry at the gate. Pflugers Arch. 451:181–192. 2005. View Article : Google Scholar : PubMed/NCBI
37	Rainone F, Arcidiacono T, Terranegra A, Aloia A, Dogliotti E, Mingione A, Spotti D, Francucci CM, Soldati L and Vezzoli G: Calcium sensing receptor and renal mineral ion transport. J Endocrinol Invest. 34(Suppl): 8–12. 2011.